Trial Profile
The effect of acute and chronic administration of the CCK1 receptor antagonist Dexloxiglumide (CR2017) on 24-h pH metry, LES motor and symptoms' pattern, in patients with gastroesophageal reflux disease (GERD). A randomized, double-blind, placebo controlled study.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2012
Price :
$35
*
At a glance
- Drugs Dexloxiglumide (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- 28 Jul 2011 New trial record